ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för alogliptin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

24 träffar

Bibliografisk träff 2013-01-09

Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.

Noda Y, Miyoshi T, Oe H, Ohno Y, Nakamura K, Toh N, Kohno K, Morita H, Kusano K, Ito H.

Cardiovasc Diabetol · research-article; randomized controlled trial; journal article · DOI 10.1186/1475-2840-12-8

Bibliografisk träff 2013-01-07

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S, Ito M, Maruyama N, Okada K, Soma M.

Expert Opin Pharmacother · clinical trial; multicenter study; journal article · DOI 10.1517/14656566.2013.761690

Bibliografisk träff 2012-12-05

Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin.

Kusunoki Y, Katsuno T, Myojin M, Miyakoshi K, Ikawa T, Matsuo T, Ochi F, Tokuda M, Murai K, Miuchi M, Hamaguchi T, Miyagawa J, Namba M.

Endocr J · comparative study; clinical trial; journal article · DOI 10.1507/endocrj.ej12-0290

Bibliografisk träff 2012-11-01

Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.

Agrawal R, Bahare RS, Jain P, Dikshit SN, Ganguly S.

Mini Rev Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/13895575112091345

Bibliografisk träff 2012-07-25

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.

Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, Drucker DJ, Vallon V.

Am J Physiol Renal Physiol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1152/ajprenal.00259.2012

Bibliografisk träff 2012-06-05

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.

Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K.

Diabetes Obes Metab · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2012.01620.x

Bibliografisk träff 2012-05-01

An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

Irons BK, Weis JM, Stapleton MR, Edwards KL.

Curr Diabetes Rev · review; journal article · DOI 10.2174/157339912800564007

Bibliografisk träff 2012-03-14

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE.

J Clin Endocrinol Metab · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1210/jc.2011-2243

Bibliografisk träff 2012-02-01

Alogliptin benzoate for the treatment of type 2 diabetes.

Rendell M, Drincic A, Andukuri R.

Expert Opin Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14656566.2012.656088

Bibliografisk träff 2012-01-17

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.

Kutoh E, Ukai Y.

Endocrine · randomized controlled trial; journal article · DOI 10.1007/s12020-012-9596-0

Bibliografisk träff 2012-01-12

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

Eliasson B, Möller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, Diamant M, Taskinen MR, Smith U.

Diabetologia · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s00125-011-2447-3

Bibliografisk träff 2011-12-12

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, Gibbs MA.

J Clin Pharmacol · meta-analysis; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1177/0091270011420153

Bibliografisk träff 2011-12-01

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

Bosi E, Ellis GC, Wilson CA, Fleck PR.

Diabetes Obes Metab · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2011.01463.x

Bibliografisk träff 2011-11-01

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y.

Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2011.01460.x

Bibliografisk träff 2011-11-01

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.

Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K.

Curr Med Res Opin · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1185/03007995.2011.614936

Bibliografisk träff 2011-08-01

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y.

J Cardiovasc Pharmacol · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1097/fjc.0b013e31821e5626

Bibliografisk träff 2011-08-01

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.

Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K.

Curr Med Res Opin · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1185/03007995.2011.599371

Bibliografisk träff 2011-05-27

Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.

Parsa KV, Pal M.

Expert Opin Drug Discov · journal article · DOI 10.1517/17460441.2011.588695

Bibliografisk träff 2011-05-01

[Alogliptin].

Tanabe A, Kaku K.

Nihon Rinsho · comparative study; review; journal article; english abstract

Bibliografisk träff 2011-05-01

[A compounding agent of alogliptin and pioglitazone].

Ueki K.

Nihon Rinsho · review; journal article

Bibliografisk träff 2011-04-01

Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.

Zhang X, Wang Z, Huang Y, Wang J.

Diabetes Obes Metab · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1463-1326.2010.01354.x

Bibliografisk träff 2011-03-10

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.

Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I, Deiuliis J, Xu X, Sun Q, Moffatt-Bruce S, Villamena F, Rajagopalan S.

Vascul Pharmacol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.vph.2011.03.001

Bibliografisk träff 2011-02-01

Alogliptin for the treatment of type 2 diabetes.

White JR.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2011.47.2.1583163

Bibliografisk träff 2010-01-01

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.

Karim A, Covington P, Christopher R, Davenport M, Fleck P, Li X, Wann E, Mekki Q.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.5414/cpp48046